이 장은 원문만 있습니다. 문장별 해석은 앞 장부터 차례로 붙입니다.
1장 · The History and Science of the Major Birch Pollen Allergen Bet v 1
The term allergy was coined in 1906 by the Austrian scientist and pediatrician Clemens Freiherr von Pirquet. In 1976, Dietrich Kraft became the head of the Allergy and Immunology Research Group at the Department of General and Experimental Pathology of the University of Vienna. In 1983, Kraft proposed to replace natural extracts used in allergy diagnostic tests and vaccines with recombinant allergen molecules and persuaded Michael Breitenbach to contribute his expertise in molecular cloning as one of the mentors of this project. Thus, the foundation for the Vienna School of Molecular Allergology was laid. With the recruitment of Heimo Breiteneder as a young molecular biology researcher, the work began in earnest, resulting in the publication of the cloning of the first plant allergen Bet v 1 in 1989. Bet v 1 has become the subject of a very large number of basic scientific as well as clinical studies. Bet v 1 is also the founding member of the large Bet v 1-like superfamily of proteins with members—based on the ancient conserved Bet v 1 fold—being present in all three domains of life, i.e., archaea, bacteria and eukaryotes. This suggests that the Bet v 1 fold most likely already existed in the last universal common ancestor. The biological function of this protein was probably related to lipid binding. However, during evolution, a functional diversity within the Bet v 1-like superfamily was established. The superfamily comprises 25 families, one of which is the Bet v 1 family, which in turn is composed of 11 subfamilies. One of these, the PR-10-like subfamily of proteins, contains almost all of the Bet v 1 homologous allergens from pollen and plant foods. Structural and functional comparisons of Bet v 1 and its non-allergenic homologs of the superfamily will pave the way for a deeper understanding of the allergic sensitization process.
Events That Led to the Discovery of the Major Birch Pollen Allergen Bet v 1
Clemens von Pirquet, a true legend of immunology, observed that antibodies were not only part of protective immune responses but could also cause diseases. He coined the word “allergy,” derived from ancient Greek (allos = other and ergon = work), to generally describe a change in the reactive capability of the immune system. He presented his findings in 1906 in the Münchener Medizinische Wochenschrift, thus introducing the term “allergy” to the medical terminology.
In 1976, Dietrich Kraft became the head of the Allergy and Immunology Research Group at the Department of General and Experimental Pathology, then of the Medical Faculty of the University of Vienna, which would become the Medical University of Vienna in 2004. In autumn 1983, Kraft turned his full focus to allergic diseases. Working in an outpatient allergy clinic in Vienna together with his colleague Herwig Ebner, he came to the insight that allergy test solutions and hyposensitization solutions could only be standardized based on pure recombinant molecules. Kraft elaborated on this idea during a lengthy stay in hospital due to a severe bicycle accident. Consequently, on 12 December 1983, he called Michael Breitenbach on the phone, as a meeting in person was impossible due to the unusually heavy snowfall that day. During this one hour call, Kraft managed to persuade Michael Breitenbach to contribute his essential expertise in molecular cloning to this newly hatched project. Thus, the keystone for the founding of the Vienna School of Molecular Allergology was put into place. Kraft also recruited Otto Scheiner and Helmut Rumpold, who brought additional expertise, i.e., immunohistochemistry and medical laboratory techniques, to the project.
From 1983 to 1984, investing in the cloning and production of recombinant allergens was of no interest for funding agencies in Austria. In a similar manner, pharmaceutical companies active in the allergy field in countries including Denmark, Sweden, Germany, and the USA did not support Kraft’s plans, deeming them to be too exotic. During a banquet held by the Austrian Society of Allergology and Immunology (ÖGAI), Kraft ended up sitting next to Jörg Mayrhofer, to whom he laid open his vision for recombinant allergens. Mayrhofer, then owner of the Schutzengel Apotheke (Guardian Angel Pharmacy) in Linz, Austria, showed an interest in Kraft’s plans as a potential business opportunity. During a follow-up visit to Linz, Jörg Mayrhofer and his father, Theodor Mayrhofer, agreed to fund Kraft’s ambitious plans. Consequently, in 1984, the company Biomay was founded that would finance all the formative years of Kraft’s team of molecular allergology.
As around 5% of the Austrian population suffer from pollinosis induced by birch pollen in early spring, and as there is only one major allergen present in birch pollen extract, this allergen was chosen as the target. Following the rules of allergen nomenclature laid down by the WHO/IUIS Allergen Nomenclature Sub-Committee and the then-valid taxonomical name for the white birch, Betula verrucosa, this allergen was designated as Bet v 1. Michael Breitenbach selected Heimo Breiteneder as the person who would be responsible for the cloning of the cDNA for Bet v 1. Breiteneder had just finished his thesis on the genome organization of the cyanelles of Cyanophora paradoxa under the guidance of Wolfgang Löffelhardt at the Institute of General Biochemistry of the University of Vienna.
On 2 May 1985, the work on the cloning of the Bet v 1 cDNA started in earnest. At first, the isolation of RNA from birch tissues needed to be established. This was done from roots of birch seedlings, and from leaves and inflorescences of mature trees. Finally, pure pollen from birch trees was obtained, RNA was isolated and poly(A)+ mRNA was enriched. This mRNA preparation was translated in vitro in a cell-free wheat germ system, and the proteins synthesized were separated by SDS-PAGE and transferred to nitrocellulose. When the blots were incubated with sera from patients allergic to birch pollen, IgE binding to a 17-kD protein, presumably Bet v 1, was observed, indicating the presence of allergen-coding mRNA in the RNA preparations. Based on this finding, the E. coli phage λgt11 was selected to produce a cDNA expression library from birch pollen poly(A)+ mRNA. Michael Breitenbach was also instrumental in obtaining further knowhow from Arnold Bito and Klaus Richter at the Academy of Sciences in Salzburg on working with phage λgt11. The expression library was going to be screened, in a manner identical to immunoblots—with sera from birch pollen allergic patients—a combination of techniques that had not been previously used.
Phage λgt11 clones containing Bet v 1-encoding cDNAs, and thus producing recombinant Bet v 1 in infected E. coli cells, were first identified on 3 July 1988. The full cDNA sequence of Bet v 1 was published in the EMBO Journal in 1989, representing the most abundant isoform in birch pollen, called Bet v 1.0101. Thus, Bet v 1 became the first cloned plant allergen and also the first allergenic PR-10-like protein that was published worldwide. Its sequence was similar to the N-terminal peptide sequences of the pollen allergens of hazel, alder and hornbeam, trees belonging to the order of Fagales and, therefore, closely related to birch. What came as a surprise was that Bet v 1 also displayed a 55% sequence identity with a pea disease resistance response gene. Pea and birch being taxonomically quite distant, this was the first indication of a gene family whose founding member must have existed a long time ago. In 1991, the cDNA sequence and recombinant protein of the alder pollen allergen Aln g 1 was published, followed in 1993 by the major allergen of hazel pollen, Cor a 1. This publication describes the identification of four cDNA clones whose open reading frames coded for different isoforms of the major hazel pollen allergen. Interestingly, recombinant proteins of these four isoforms displayed differing IgE binding capacities. In 1995, the cDNAs and recombinant proteins of the major allergens of apple, Mal d 1, and of celery, Api g 1, joined the ranks of allergenic PR-10-like proteins, thus firmly establishing the presence of members of this gene family in the plant kingdom.
TOEFL® 읽기 문제 5문항. 이 장의 한 대목을 그대로 옮기고 문항을 붙였습니다. 대목을 읽고 문제를 풉니다.
이 글은 위 출처의 원문을 그 라이선스(CC BY 4.0)에 따라 옮겼습니다. 참고문헌 목록과 인용 번호, 그림 · 표 · 각주 · 수식 · 부록은 빼고 절별로 나누어 실었으며, 그 밖의 문장은 원문 그대로입니다. 원 저작자와 발행 기관은 이 화면을 만들거나 검토하지 않았고, 이곳의 해석과 낱말 풀이는 공식 번역이 아닙니다.
